Rituximab therapy for Takayasu arteritis: A seven patients experience and a review of the literature

Rheumatology (United Kingdom)

Volumn 57, Issue 7, 2018, Pages 1151-1155

  Pazzola, Giulia ^a,b   Muratore, Francesco ^a,b   Pipitone, Nicoló ^a   Crescentini, Filippo ^a   Cacoub, Patrice ^c,d   Boiardi, Luigi ^a   Spaggiari, Lucia ^a   Comarmond, Cloe ^c,d   Croci, Stefania ^a   Saadoun, David ^c,d   Salvarani, Carlo ^a,b  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Unit of Dermatology   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

Disease activity; Rituximab; Takayasu arteritis

Indexed keywords

ADALIMUMAB; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

ADULT; AORTIC ARCH SYNDROME; ARTICLE; BIOLOGICAL THERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE ACTIVITY; DISEASE SEVERITY ASSESSMENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KERR INDEX; LABORATORY TEST; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; MULTIMODAL IMAGING; PERSONAL EXPERIENCE; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; RETROSPECTIVE STUDY; TREATMENT REFUSAL; YOUNG ADULT;

EID: 85051483673     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kex249     Document Type: Article

References (20)

1. Kerr GS, Hallahan CW, Giordano J et al. Takayasu arteritis. Ann Intern Med 1994;120:919-29.
2. Kötter I, Henes JC, Wagner AD et al. Does glucocorticosteroid-resistant large vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature. Clin Exp Rheumatol 2012;30(Suppl 70):S114-29.
3. Inder SJ, Bobryshev YV, Cherian SM et al. Immunophenotypic analysis of the aortic wall in Takayasu's arteritis: involvement of lymphocytes, dendritic cells and granulocytes in immuno-inflammatory reactions. Cardiovasc Surg 2000;8:141-8.
4. Hoyer BF, Mumtaz IM, Loddenkemper K et al. Takayasu arteritis is characterised by disturbances of B cell homeostasis and responds to B cell depletion therapy with rituximab. Ann Rheum Dis 2012;71:75-9.
5. Arend WP, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990;33:1129-34.
6. Caltran E, Di Colo G, Ghigliotti G. Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 2014;33:1183-4.
7. Galarza C, Valencia D, Tobón GJ et al. Should rituximab be considered as the first-choice treatment for severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 2008;34:124-8.
8. Ernst D, Greer M, Stoll M et al. Remission achieved in refractory advanced Takayasu arteritis using rituximab. Case Rep Rheumatol 2012;2012:406963.
9. Walters HM, Aguiar CL, Macdermott EJ et al. Takayasu arteritis presenting in the context of active tuberculosis: a pediatric case. Clin Rheumatol 2013;19:344-7.
10. Hoffman GS, Leavitt RY, Kerr GS et al. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994;37:578-82.
11. Misra DP, Sharma A, Kadhiravan T, Negi VS. A scoping review of the use of non-biologic disease modifying antirheumatic drugs in the management of large vessel vasculitis. Autoimmun Rev 2017;16:179-91.
12. Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014;26:7-15.
13. Loricera J, Blanco R, Herná ndez JL et al. Tocilizumab in patients with Takayasu arteritis: a retrospective study and literature review. Clin Exp Rheumatol 2016;34(Suppl 97):S44-53.
14. Salvarani C, Magnani L, Catanoso M et al. Tocilizumab: a novel therapy for patients with large vessel vasculitis. Rheumatology 2012;51:151-6.
15. Pazzola G, Muratore F, Pipitone N, Salvarani C. Biotherapies in large vessel vasculitis. Rev Med Interne 2016;37:274-8.
16. Cañas CA, Cañas F, Izquierdo JH et al. Efficacy and safety of anti-interleukin 6 receptor monoclonal antibody (tocilizumab) in Colombian patients with Takayasu arteritis. J Clin Rheumatol 2014;20:125-9.
17. Sima D, Thiele B, Turowski A et al. Anti-endothelial antibodies in Takayasu arteritis. Arthritis Rheum 1994;37:441-3.
18. Wang H, Ma J, Wu Q et al. Circulating B lymphocytes producing autoantibodies to endothelial cells play a role in the pathogenesis of Takayasu arteritis. J Vasc Surg 2011;53:174-80.
19. Nishino Y, Tamai M, Kawakami A et al. Serum levels of BAFF for assessing the disease activity of Takayasu arteritis. Clin Exp Rheumatol 2010;28(Suppl 57):14-7.
20. Maritati F, Corradi D, Versari A et al. Rituximab therapy for chronic periaortitis. Ann Rheum Dis 2012;71:1262-4.